Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~1. Healthy male and female subjects~2. Subjects must be able to understand and comply with study requirements~3. Age 18 to 50 years~4. Body mass index (BMI) 18.5 to 29.9 kg/m2~Exclusion criteria:~1. Any relevant deviation from healthy conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- FDC empagliflozin dose 1 and metformin (Type: EXPERIMENTAL): fix dose combination tablet after intake of a high fat, high caloric meal
- empagliflozin dose 1 + metformin tablets (Type: ACTIVE_COMPARATOR): single tablets after intake of a high fat, high caloric meal
- FDC empagliflozin dose 2 and metformin (Type: EXPERIMENTAL): fix dose combination tablet after intake of a high fat, high caloric meal
- empagliflozin dose 2 + metformin tablets (Type: ACTIVE_COMPARATOR): single tablets after intake of a high fat, high caloric meal

Based on this trial design, predict the completion outcome and termination type (if applicable).